Revolution Medicines wins EU approval for Rasonque in pancreatic cancer
FROM THE WIRE · FINANCE.YAHOO.COM
Revolution Medicines RVMD announced that the European Commission (EC) has approved its once-daily oral pill Rasonque (daraxonrasib) for adults with metastatic pancreatic ductal adenocarcinoma (PDAC) who have received at least one prior systemic therapy. The approval covers…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe European approval of an oral cancer drug expands Revolution Medicines' market, a positive for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The European Commission approved Rasonque (daraxonrasib) for metastatic PDAC.
- 02The approval covers adults who received at least one prior systemic therapy.
- 03The phase III RASolute 302 study showed a 60% reduction in risk of death versus chemotherapy.
- 04The FDA had already approved the drug for a similar indication in August 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets